POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due to ischemic cardiomyopathy to receive transendocardial infusion of allogeneic vs. autologous mesenchymal stem cells. At 13 months, adverse events were 33.3% for the allogeneic group vs. 53.3% for the autologous group (p=0,46). The group treated with autologous cells improved during test process, but not the allogeneic group. Neither of the two groups improved oxygen consumption or ejection fraction.

Conclusion: this is the first trial to show a significative absence of autoimmune reaction in patients receiving allogeneic cells.

Comment: the pilot study is limited by a small sample and the absence of a control group. However, safety data regarding allogeneic cells infusion with no need of immunosuppression are encouraging.

3_joshua_hare
Joshua Hare
2012-11-06

Original title: Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy (Poseidon)

More articles by this author

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It...

SWISS AMI: Stem cells infusion after primary angioplasty

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or...

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with...

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...